Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Paul Fagan
AddedFeb 17, 2024
UpdatedMay 31, 2026
Paul Fagan

Paul Fagan

Founder, Three Rivers Pharmaceuticals

CrunchbaseLinkedInThe Org

Paul Fagan's Career

Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals

Warrendale, PA, US

Founder
ECM Therapeutics
ECM Therapeutics

Warrendale, PA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Paul Fagan's Career

Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals
Public$6.6M1752000Warrendale, PA, US
Founder

Similar to Three Rivers Pharmaceuticals

Pyros PharmaceuticalsPyros PharmaceuticalsParsippany-Troy Hills, NJ, USGeneric Drugsest. 2017Pyros PharmaceuticalsParsippany-Troy Hills, NJ, US · est. 2017

Pyros Pharmaceuticals: Developing and commercializing affordable generic drugs.

Public · $880k40
PharmstandardPharmstandardDolgoprudny, Moscow, RUMedical Equipment, Pharmaceuticalsest. 2003PharmstandardDolgoprudny, Moscow, RU · est. 2003

Pharmstandard PJSC, a Russian company, manufactures generic pharmaceuticals and medical equipment.

Public6.5k
Tris PharmaTris PharmaMonmouth Junction, NJ, USPharmaceuticalsest. 2000Tris PharmaMonmouth Junction, NJ, US · est. 2000

Tris Pharma, a New Jersey-based medical organization, innovates drug delivery technologies and medicines for disease treatment.

Public · $141.6M350
ECM Therapeutics
ECM Therapeutics
$37M82018Warrendale, PA, US
CEO· C-Suite · Management

Leadership at ECM Therapeutics

Stephen BadylakStephen BadylakCo-Founder
Katie CollinsKatie CollinsCo-Founder

Similar to ECM Therapeutics

ECM TechnologiesECM TechnologiesHouston, TX, USBiomaterials, Collagensest. 2007ECM TechnologiesHouston, TX, US · est. 2007

ECM Technologies: Innovating regenerative medicine with customizable, non-animal derived Designer Collagens.

$280k30
TissueFormTissueFormBoulder, CO, USBiomaterialsest. 2019TissueFormBoulder, CO, US · est. 2019

TissueForm: Advancing biomaterials for regenerative medicine and plastic surgery solutions.

$250k2
NeXtGen BiologicsNeXtGen BiologicsAlachua, FL, USMedical Devicesest. 2014NeXtGen BiologicsAlachua, FL, US · est. 2014

NeXtGen Biologics, a Florida-based medical device company, innovates ECM products since 2014.

$1.9M9
EndoCellutionsEndoCellutionsMarshfield, MA, USMedical Devicesest. 2010EndoCellutionsMarshfield, MA, US · est. 2010

Leading provider of innovative regenerative medicine solutions, bridging devices and biologics.

$900.1k7

People Similar to Paul Fagan

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailBrian KimBrian KimCo-Founder · KakaoKim Beom-sooKim Beom-sooCo-Founder · KakaoDan O'DayDan O'DayCo-Founder · EcfxKevin GromanKevin GromanCo-Founder · Sonoran Founders FundJoerg HeuerJoerg HeuerCo-Founder · EcoGMagnus HookMagnus HookCo-Founder · ECM TechnologiesJoe StarksJoe StarksCEO · ECC Technologies